Abstract
Presenilin (PS) was identified in screens for mutations causing the early onset forms of familial Alzheimer's disease (FAD) in 1995. As catalytic units of the γ-secretase complex, presenilins participate in the processing of amyloid beta protein (Aβ), the main component of deposits in brain of patients with AD. The more than 90 substrates of γ-secretase isolated so far demonstrate its contribution to wide range of cellular processes and signaling events. However, recent findings have revealed numerous γ-secretase-independent presenilin functions, including involvement in calcium homeostasis, endoplasmic reticulum (ER) stress and autophagy. This mini-review attempts to summarize the multiple physiological and pathological functions of presenilin.
Keywords: Autophagy, Ca2+ signaling, presenilin, ER stress, γ-secretase, neurodegenerative disease.
Current Pharmaceutical Biotechnology
Title:Physiological Functions of Presenilins; Beyond γ-Secretase
Volume: 15 Issue: 11
Author(s): Ibolya Stiller, Beata Lizak and Gabor Banhegyi
Affiliation:
Keywords: Autophagy, Ca2+ signaling, presenilin, ER stress, γ-secretase, neurodegenerative disease.
Abstract: Presenilin (PS) was identified in screens for mutations causing the early onset forms of familial Alzheimer's disease (FAD) in 1995. As catalytic units of the γ-secretase complex, presenilins participate in the processing of amyloid beta protein (Aβ), the main component of deposits in brain of patients with AD. The more than 90 substrates of γ-secretase isolated so far demonstrate its contribution to wide range of cellular processes and signaling events. However, recent findings have revealed numerous γ-secretase-independent presenilin functions, including involvement in calcium homeostasis, endoplasmic reticulum (ER) stress and autophagy. This mini-review attempts to summarize the multiple physiological and pathological functions of presenilin.
Export Options
About this article
Cite this article as:
Stiller Ibolya, Lizak Beata and Banhegyi Gabor, Physiological Functions of Presenilins; Beyond γ-Secretase, Current Pharmaceutical Biotechnology 2014; 15 (11) . https://dx.doi.org/10.2174/1389201015666141122204139
DOI https://dx.doi.org/10.2174/1389201015666141122204139 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therapy
Current Medicinal Chemistry An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Anti-Cancer Agents in Medicinal Chemistry Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews In Vivo Apoptosis Imaging Agents and Strategies
Anti-Cancer Agents in Medicinal Chemistry Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology The Microarray Gene Profiling Analysis of Glioblastoma Cancer Cells Reveals Genes Affected by FAK Inhibitor Y15 and Combination of Y15 and Temozolomide
Anti-Cancer Agents in Medicinal Chemistry Perspectives/Opinion: ADVANCED MEDICAL IMAGING IN THE ERA OF PERSONALIZED OR PRECISION MEDICINE
Current Medical Imaging AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets An Integrative Systems Analysis of High-grade Glioma Cell Lines: TLRs, Wnt, BRCA1, Netrins, STXBP1 and MDH1 Provide Putative Molecular Targets for Therapeutic Intervention
Current Pharmacogenomics and Personalized Medicine New Trends of Deep Learning in Clinical Cardiology
Current Bioinformatics Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery
Recent Patents on Inflammation & Allergy Drug Discovery Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design Erlotinib in Glioblastoma - Lost in Translation?
Anti-Cancer Agents in Medicinal Chemistry Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry